Key result
Schizophrenia links to ~96% higher in-hospital mortality and fewer cardioprotective meds in young HF patients.
Why the study?
There is limited knowledge regarding in-hospital prognosis and quality of care for patients with schizophrenia hospitalized for heart failure.
Does comorbid schizophrenia increase in-hospital mortality and reduce the prescription of cardioprotective medications in patients hospitalized with heart failure?
Population
704,193 patients hospitalized with HF in Japan
Comparison
Patients with schizophrenia vs without schizophrenia
Design
Nationwide registry-based cohort study
Authors
Loading...
May support closer monitoring in young HF patients with schizophrenia; leaves open whether closing GDMT gaps improves survival.
Cohort (n=704,193)
Yes
Does comorbid schizophrenia increase in-hospital mortality and reduce the prescription of cardioprotective medications in patients hospitalized with heart failure?
Effect estimate: OR 1.96 (95% CI 1.24-3.10)
Absolute Event Rate: 7.6% vs 3.5%
p-value: p=0.0037
Comorbid schizophrenia is an independent risk factor for in-hospital mortality and is associated with significantly lower prescription rates of guideline-directed medical therapies in non-elderly patients hospitalized with heart failure.
Nishi et al. (2023) conducted a cohort in Heart failure (n=704,193). Schizophrenia vs. Without schizophrenia was evaluated on All in-hospital mortality (young adults aged 18-45 years) (OR 1.96, 95% CI 1.24-3.10, p=0.0037). Schizophrenia was associated with significantly higher in-hospital mortality (OR 1.96) and reduced prescription of cardioprotective medications in young adult patients hospitalized with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: